Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: AbbVie announces availability of ELAHERE in Singapore for the treatment of platinum-resistant Ovarian cancer AbbVie announced the availability of ELAHERE, the first folate receptor alpha-targeted antibody-drug conjugate, […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: China NMPA approves Zai Lab’s TIVDAK for recurrent or metastatic Cervical cancer Zai Lab has received approval from China’s National Medical Products Administration for TIVDAK for the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 11 June 2026: CDSCO approves Trastuzumab deruxtecan plus Pertuzumab for first-line HER2-positive metastatic Breast cancer AstraZeneca Pharma India has received CDSCO approval for Enhertu in combination with pertuzumab as a […]
Weekly Digest – May 2026 Weekly Digest – May 2026 27 May 2026: U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer AbbVie has secured U.S. FDA approval for DECNUPAZ in blastic plasmacytoid dendritic cell […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic Breast cancer and 2L HER2-positive metastatic Gastric cancer Enhertu has secured […]
Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma GSK has announced that China’s NMPA has approved Blenrep in combination with bortezomib and dexamethasone for […]
Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma RemeGen has received approval in China for disitamab vedotin (RC48, Aidixi) in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 27 March 2026: ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer ENHERTU in combination […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma Chugai has received approval in Japan (MHLW) […]
Weekly Digest – February 2026 Weekly Digest – February 2026 06 February 2026: Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer Sichuan Kelun-Biotech announced that China’s National Medical Products Administration has approved a […]
